Rsv Vacc, Pref A And Pref B/Pf
Brand name: Abrysvo
Rank #63 of 500 drugs by total cost
$284.5M
Total Cost
872,396
Total Claims
$284.5M
Total Cost
6,599
Prescribers
$326
Cost per Claim
871,769
Beneficiaries
873,427
30-Day Fills
$43K
Avg Cost/Provider
132
Avg Claims/Provider
About Rsv Vacc, Pref A And Pref B/Pf
Rsv Vacc, Pref A And Pref B/Pf (sold as Abrysvo) was prescribed 872,396 times by 6,599 Medicare Part D providers in 2023, costing the program $284.5M. At $326 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 60 | Umeclidinium Brm/Vilanterol Tr (Anoro Ellipta) | $294.3M | 480,651 |
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
| 63 | Rsv Vacc, Pref A And Pref B/Pf (Abrysvo) | $284.5M | 872,396 |
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology